New Osteoporosis Treatment That Could Benefit Thousands

MBST treatment for osteoporosis

For the first time in a decade, a new treatment has been approved that could benefit thousands of people suffering with Osteoporosis. Approved by NICE (National Institute for Health and Care Excellence), Romosozumab provides greater protection than traditional treatments to prevent broken bones.

So, what is the new treatment for osteoporosis and how does it compare to current treatments available to patients? Find out everything you need to know below.

Understanding the new bone treatment

Romosozumab is a drug that helps to slow down the cells responsible for breaking down bone. At the same time, it speeds up the production of cells that build bones known as osteoblasts. This makes it highly effective at reducing bone loss, while building up strength in the bones.

While it may have only just been approved for use in the UK, the FDA approved the drug as an Osteoporosis treatment back in 2019. It is especially useful in the treatment of severe Osteoporosis in menopausal women.

In the latest clinical trial, a group of patients took the drug before alendronic acid. It was discovered that this helped to reduce their relative risk of vertebral fractures by 50%, over a period of 24 months. The risk of developing non-vertebral fractures was also decreased by 19% compared to those who only took alendronic acid.

These results mean that Romosozumab could potentially help around 20,000 patients who currently experience severe Osteoporosis on the NHS.

What is Osteoporosis?

Osteoporosis is a bone-weakening disease that leads to fragile and thin bones. It is thought that the condition directly leads to almost 9 million fractures globally every year. While it can impact both sexes, women going through the menopause tend to be at a higher risk due to hormone changes.

Osteoporosis becomes an increasing concern the older you get. In women aged 50, the risk of developing the condition is around 2%. However, women aged 80 and over see an increased risk of 25%.

The disease tends to affect the joints such as the knees and hips. However, it can also impact other areas such as the spine and the wrists.

What current treatments are available?

Current treatments available alendronic acid, bisphosphonates, and denosumab. Medications can help, but largely for patients with mild or moderate forms of the disease. Another type of treatment currently available that has shown one of the highest rates of success is MBST.

MBST addresses the root cause of Osteoporosis, bone metabolism. It transfers energy to the tissue of the bones, encouraging regrowth of the bone and cartilage. It also acts as a pain-reliever and anti-inflammatory, helping to eliminate the pain caused by the condition.

To find out if MBST could be an ideal treatment for Osteoporosis, book a consultation with MBST London today.